VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of ...

HIGH WYCOMBE, UK, 28th April 2005 – Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced that the European Commission has approved the use of VELCADE® (bortezomib) for ...

VELCADE (R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation Dec 10, 2007 5:19pm Biotech ...

The Phase II prospective, single-arm study led by Dr. Richardson assessed the safety and efficacy of VELCADE in 66 patients with untreated, symptomatic MM. Patients received single-agent VELCADE 1.3mg ...

"We designed this trial to combine three active agents in NHL with the goal of enhancing the clinical outcomes of this patient population," said Nancy Simonian, M.D., Chief Medical Officer, Millennium ...

This approval extends the benefit of VELCADE for mantle cell lymphoma (MCL) to previously untreated patients in addition to relapsed or refractory patients First treatment approved by the U.S. Food ...

Co reported on the presentation of results from clinical trials of Velcade based therapies that showed high complete remission / complete response rates in previously treated multiple myeloma patients ...

Findings published in the April 15th issue of Blood show that a team of researchers led by Millennium Pharmaceuticals, Inc. has discovered biomarkers which may lead to identifying multiple myeloma ...

CAMBRIDGE, Mass., Nov. 18 Millennium: The Takeda OncologyCompany today announced that 120 data presentations concerning VELCADEresearch will be featured at the 50th American Society of Hematology (ASH ...

Hyderabad, July 27 Dr Reddy’s Laboratories has launched Bortezomib for Injection, the generic equivalent of Velcade (bortezomib) Injection, in the US market, approved by the US Food and Drug ...